Öz
Kaynakça
- 1. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: How hot is the link?. Biochem Pharmacol 2006; 72: 1605-21.
- 2. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-7.
- 3. Li F, Tiede B, Massagué J. Kang Y. Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res 2007; 17: 3-14.
- 4. Makgoeng SB, Bolanos RS, Jeon CY, Weiss RE, Arah OA, Breen EC, et al. Markers of Immune Activation and Inflammation, and NonHodgkin Lymphoma: A Meta-Analysis of Prospective Studies. JNCI Cancer Spectrum 2018; 2: pky082
- 5. Poppema S, Potters M, Emmens R, Visser L, van den Berg A. Immune reactions in classical Hodgkin’s lymphoma. Semin Hematol 1999; 36: 253-9.
- 6. Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis Hodgkin’s lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol 2011; 29: 1812-26.
- 7. Schottenfeld D, Beebe-Dimmer J. Chronic Inflammation: A Common and Important Factor in the Pathogenesis of Neoplasia. CA Cancer J Clin 2006; 56: 69-83.
- 8. Gupta M, Han JJ, Stenson M, Maurer M, Wellik L, Hu G, et al. Elevated serum IL-10 levels in diffuse large B–cell lymphoma: A mechanism of aberrant JAK2 activation. Blood 2012; 119: 2844-53.
- 9. Yeh ET. CRP as a mediator of disease. Circulation 2004; 109: II11-4.
- 10. Li S, Rong H, Guo Q, Chen Y, Zhang G, Yang J. Serum procalcitonin levels distinguish gram-negative bacterial sepsis from grampositive bacterial and fungal sepsis. J Res Med Sci 2016; 21: 39-46.
- 11. Matzaraki V, Alexandraki KI, Venetsanou K, Piperi C, Myrianthefs P, Malamos N, et al. Evaluation of serum procalcitonin and interleukin-6 levels of liver metastasis. Clin Biochem 2007; 40: 336-42.
- 12. Zielinski CC, Preis P, Aiginger P, Eibl MM. Acute-phase-proteins and parameters of humoral immunity in patients with advanced Hodgkin’s disease. J Cancer Res Clin Oncol 1985; 110: 65-70.
- 13. Legouffe E, Rodriguez C, Picgt MC, Richard B, Klein B, Rossi JF, et al. C-reactive protein serum level is a valuable and simple prognostic marker in non-Hodgkin’s lymphoma. Leuk Lymphoma 1998; 31: 351-7.
- 14. Wieland A, Kerbl R, Berghold A, Schwinger W, Mann G, Urban C. C-reactive protein (CRP) as tumor marker in pediatric and adolescent patients with Hodgkin disease. Med Pediatr Oncol 2003; 41: 21-5.
- 15. Weinstein PS, Skinner M, Sipe JD, Lokich JJ, Zamcheck N, Cohen AS. Acute-phase proteins or tumour markers: the role of SAA, SAP, CRP and CEA as indicators of metastasis in a broad spectrum of neoplastic diseases. Scand J Immunol 1984; 19: 193-8.
- 16. Cao Y, Shi YX, Chen JO, Tan YT, Cai YC, Luo HY, et al. Serum C-reactive protein as an important prognostic variable in patients with diffuse large B cell lymphoma. Tumour Biol 2012; 33: 1039-44.
- 17. Da Silveira da Rocha TM, Miranda Silva AL, Fortier SC, Chiattone CS. Evaluation correlates C-reactive protein with advanced stage Hodgkin’s lymphoma and response to treatment in a tertiary university hospital in Brazil. Rev Bras Hematol Hemoter 2015; 37: 242-6.
- 18. Haase R, Vilser C, Mauz-Körholz C, Hasenclever D, Kluge R, Ruschke K, et al. Evaluation of the prognostic meaning of C-reactive protein (CRP) in children and adolescents with classical Hodgkin’s lymphoma (HL). Klin Padiatr 2012; 224: 377-81.
- 19. Chaftari AM, Hachem R, Reitzel R, Jordan M, Jiang Y, Yousif A, et al. Role of Procalcitonin and Interleukin-6 in Predicting Cancer, and Its Progression Independent of Infection. PLoS One 2015; 10: 1-11.
- 20. Kawaguchi Y, Saito B, Nakata A, Matsui T, Sasaki Y, Shimada S, et al. Elevated C-reactive protein level is associated with poor prognosis in follicular lymphoma patients undergoing rituximabcontaining chemotherapy. Int J Hematol 2020; 112: 341-8.
Öz
Objective: Increased inflammatory cells in the tumor microenvironment are important in the formation and progression of lymphomas. C-reactive protein (CRP) and procalcitonin (PCT) are biomarkers that can be used to detect infection and inflammation. We investigated the clinical significance of CRP and PCT levels in lymphoma cases.
Materials and Methods: We evaluated 82 Hodgkin and 120 diffuse large B-cell lymphoma (DLBCL) cases. Pre- and post-treatment PCT and CRP values were compared. The relationship between pre-treatment CRP and PCT levels and response to chemotherapy treatment, disease stage, performance score, extranodal involvement, presence of bulky mass, and bone marrow involvement was determined.
Results: In the Hodgkin lymphoma group, the CRP level was increased in 40 (48.8%) patients and the PCT level was increased in 16 (19.5%) patients. The CRP level was high in 36 (30%) cases and the PCT level was high in 34 (18.3%) cases in the DLBCL group. CRP and PCT levels were significantly lower after chemotherapy treatment in all of our cases compared to pretreatment (p<0.001, p<0.001, respectively).
Conclusion: The decrease in CRP and PCT levels after chemotherapy treatment in our Hodgkin and DLBCL cases compared with pretreatment supports the role of inflammation in the pathogenesis. In addition, these parameters may contribute to the determination of prognosis.
Anahtar Kelimeler
Procalcitonin C-reactive protein Hodgkin lymphoma diffuse large B-cell lymphoma prognosis
Kaynakça
- 1. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: How hot is the link?. Biochem Pharmacol 2006; 72: 1605-21.
- 2. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-7.
- 3. Li F, Tiede B, Massagué J. Kang Y. Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res 2007; 17: 3-14.
- 4. Makgoeng SB, Bolanos RS, Jeon CY, Weiss RE, Arah OA, Breen EC, et al. Markers of Immune Activation and Inflammation, and NonHodgkin Lymphoma: A Meta-Analysis of Prospective Studies. JNCI Cancer Spectrum 2018; 2: pky082
- 5. Poppema S, Potters M, Emmens R, Visser L, van den Berg A. Immune reactions in classical Hodgkin’s lymphoma. Semin Hematol 1999; 36: 253-9.
- 6. Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis Hodgkin’s lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol 2011; 29: 1812-26.
- 7. Schottenfeld D, Beebe-Dimmer J. Chronic Inflammation: A Common and Important Factor in the Pathogenesis of Neoplasia. CA Cancer J Clin 2006; 56: 69-83.
- 8. Gupta M, Han JJ, Stenson M, Maurer M, Wellik L, Hu G, et al. Elevated serum IL-10 levels in diffuse large B–cell lymphoma: A mechanism of aberrant JAK2 activation. Blood 2012; 119: 2844-53.
- 9. Yeh ET. CRP as a mediator of disease. Circulation 2004; 109: II11-4.
- 10. Li S, Rong H, Guo Q, Chen Y, Zhang G, Yang J. Serum procalcitonin levels distinguish gram-negative bacterial sepsis from grampositive bacterial and fungal sepsis. J Res Med Sci 2016; 21: 39-46.
- 11. Matzaraki V, Alexandraki KI, Venetsanou K, Piperi C, Myrianthefs P, Malamos N, et al. Evaluation of serum procalcitonin and interleukin-6 levels of liver metastasis. Clin Biochem 2007; 40: 336-42.
- 12. Zielinski CC, Preis P, Aiginger P, Eibl MM. Acute-phase-proteins and parameters of humoral immunity in patients with advanced Hodgkin’s disease. J Cancer Res Clin Oncol 1985; 110: 65-70.
- 13. Legouffe E, Rodriguez C, Picgt MC, Richard B, Klein B, Rossi JF, et al. C-reactive protein serum level is a valuable and simple prognostic marker in non-Hodgkin’s lymphoma. Leuk Lymphoma 1998; 31: 351-7.
- 14. Wieland A, Kerbl R, Berghold A, Schwinger W, Mann G, Urban C. C-reactive protein (CRP) as tumor marker in pediatric and adolescent patients with Hodgkin disease. Med Pediatr Oncol 2003; 41: 21-5.
- 15. Weinstein PS, Skinner M, Sipe JD, Lokich JJ, Zamcheck N, Cohen AS. Acute-phase proteins or tumour markers: the role of SAA, SAP, CRP and CEA as indicators of metastasis in a broad spectrum of neoplastic diseases. Scand J Immunol 1984; 19: 193-8.
- 16. Cao Y, Shi YX, Chen JO, Tan YT, Cai YC, Luo HY, et al. Serum C-reactive protein as an important prognostic variable in patients with diffuse large B cell lymphoma. Tumour Biol 2012; 33: 1039-44.
- 17. Da Silveira da Rocha TM, Miranda Silva AL, Fortier SC, Chiattone CS. Evaluation correlates C-reactive protein with advanced stage Hodgkin’s lymphoma and response to treatment in a tertiary university hospital in Brazil. Rev Bras Hematol Hemoter 2015; 37: 242-6.
- 18. Haase R, Vilser C, Mauz-Körholz C, Hasenclever D, Kluge R, Ruschke K, et al. Evaluation of the prognostic meaning of C-reactive protein (CRP) in children and adolescents with classical Hodgkin’s lymphoma (HL). Klin Padiatr 2012; 224: 377-81.
- 19. Chaftari AM, Hachem R, Reitzel R, Jordan M, Jiang Y, Yousif A, et al. Role of Procalcitonin and Interleukin-6 in Predicting Cancer, and Its Progression Independent of Infection. PLoS One 2015; 10: 1-11.
- 20. Kawaguchi Y, Saito B, Nakata A, Matsui T, Sasaki Y, Shimada S, et al. Elevated C-reactive protein level is associated with poor prognosis in follicular lymphoma patients undergoing rituximabcontaining chemotherapy. Int J Hematol 2020; 112: 341-8.
Ayrıntılar
| Birincil Dil | İngilizce |
|---|---|
| Konular | Klinik Tıp Bilimleri (Diğer) |
| Bölüm | Araştırma Makalesi |
| Yazarlar | |
| Yayımlanma Tarihi | 30 Haziran 2023 |
| Yayımlandığı Sayı | Yıl 2023 Cilt: 24 Sayı: 2 |